Frazier Life Sciences Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Jade Biosciences
JBIO
|
+$60.3M |
| 2 |
Zai Lab
ZLAB
|
+$31.5M |
| 3 |
Aura Biosciences
AURA
|
+$29.8M |
| 4 |
Evolus
EOLS
|
+$24.9M |
| 5 |
Cytokinetics
CYTK
|
+$19.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rhythm Pharmaceuticals
RYTM
|
+$36M |
| 2 |
Soleno Therapeutics
SLNO
|
+$35.7M |
| 3 |
Merus
MRUS
|
+$15.7M |
| 4 |
Acadia Pharmaceuticals
ACAD
|
+$7.81M |
| 5 |
Rocket Pharmaceuticals
RCKT
|
+$7.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.84% |
| 2 | Miscellaneous | 0.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
Immatics
IMTX
$1.09B
| – | – |
-1,247,911
| Closed | -$5.63M | – |
|
|
52
DELISTED
Merus
MRUS
| – | – |
-373,100
| Closed | -$15.7M | – |
|
|
53
Rocket Pharmaceuticals
RCKT
$259M
| – | – |
-1,079,025
| Closed | -$7.2M | – |
|
|
54
Rhythm Pharmaceuticals
RYTM
$6.06B
| – | – |
-678,760
| Closed | -$36M | – |
|
|
55
DELISTED
Soleno Therapeutics
SLNO
| – | – |
-499,159
| Closed | -$35.7M | – |
|
Similar funds
Frazier Life Sciences Management's Q2 2025 Portfolio in Review
As of Q2 2025, Frazier Life Sciences Management held 55 positions worth $2.5B, up 14% from $2.19B the previous quarter. Its ten largest holdings account for 68% of the portfolio.
Frazier Life Sciences Management deployed $193M of net new capital in Q2 2025, opening 8 new positions and adding to 16 existing holdings. Its largest new stake was Jade Biosciences: 1,772,116 shares worth $17.7M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was Verona Pharma, an estimated $5.47M trimmed.
- Frazier Life Sciences Management's largest Q2 2025 buy was Jade Biosciences: 1,772,116 shares worth $17.7M.
- Frazier Life Sciences Management added most to Zai Lab in Q2 2025, an estimated $31.5M increase.
- Frazier Life Sciences Management's biggest Q2 2025 reduction was Verona Pharma, cutting an estimated $5.47M.
- Frazier Life Sciences Management fully exited Rhythm Pharmaceuticals in Q2 2025, selling an estimated $36M.
- Frazier Life Sciences Management's ten largest holdings make up 68% of its $2.5B portfolio in Q2 2025.
- Frazier Life Sciences Management opened 8 new positions and closed 6 in Q2 2025.
- Frazier Life Sciences Management's portfolio value rose 14% quarter-over-quarter to $2.5B.
Based on Frazier Life Sciences Management's 13F filing for Q2 2025, filed 14 Aug 2025.